Crimean-Congo hemorrhagic fever
| Autor: | Ioannis N. Pierroutsakos, Helen C. Maltezou, Regina Vorou |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Microbiology (medical)
Crimean–Congo hemorrhagic fever business.industry Transmission (medicine) Zoonosis Late stage Disease medicine.disease Hemorrhagic fever virus Antiviral Agents Virology Ticks Infectious Diseases Zoonoses Hemorrhagic Fever Virus Crimean-Congo Ribavirin parasitic diseases Case fatality rate Animals Humans Medicine Hemorrhagic Fever Crimean business |
| Zdroj: | Current Opinion in Infectious Diseases. 20:495-500 |
| ISSN: | 0951-7375 |
| DOI: | 10.1097/qco.0b013e3282a56a0a |
| Popis: | Crimean-Congo hemorrhagic fever is a tick-borne viral zoonosis with the potential of human-to-human transmission, affecting wide areas in Asia, Southeastern Europe, and Africa. Hemorrhagic manifestations constitute a prominent symptom of late stage disease with case fatality rates from 10% to 50%. The purpose of this article is to review recent literature on Crimean-Congo hemorrhagic fever with emphasis on its epidemiology and management.Climate and environmental changes may affect Crimean-Congo hemorrhagic fever epidemiology and trigger community outbreaks. Risk factors for acquisition of infection have been well studied. In the hospital, high-risk activities include interventions for gastrointestinal bleeding and needle stick injuries. Reverse transcription-polymerase chain reaction may rapidly diagnose Crimean-Congo hemorrhagic fever with high sensitivity and specificity. Ribavirin is the only promising therapeutic agent currently available but case-control studies have not been conducted. Recently, the Mx proteins have been found to act against Crimean-Congo hemorrhagic fever virus and deserve further research.Clinicians should be aware of the potential of importation of Crimean-Congo hemorrhagic fever cases from endemic areas and nosocomial transmission. Studies on the efficacy of ribavirin are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|